Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results
SAN CARLOS, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its second quarter …